Champions Oncology, Inc. (CSBR) is a publicly traded Healthcare sector company. As of May 21, 2026, CSBR trades at $5.99 with a market cap of $84.29M and a P/E ratio of 17.65. CSBR moved +0.00% today. Year to date, CSBR is -9.16%; over the trailing twelve months it is +2.20%. Its 52-week range spans $3.75 to $11.99. Rallies surfaces CSBR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CSBR news today?
Champions Oncology Q3 Services Revenue Rises 32% to $16.6M, EBITDA Positive: Champions Oncology reported Q3 services revenue record with core study revenue up 32% to $16.6M, delivering a third straight quarter of positive adjusted EBITDA at $575K. Total revenue slid 3% to $16.6M due to absence of data income and gross margin narrowed to 47% from 61%.
Mendelson Daniel Newman bought 1.00K (~$6.50K) on Jan 12, 2024.
Mendelson Daniel Newman bought 2.00K (~$12.54K) on Jan 11, 2024.
Mendelson Daniel Newman bought 2.94K (~$18.58K) on Jan 10, 2024.
CSBR Analyst Consensus
CSBR analyst coverage data. Average price target: $0.00.
Common questions about CSBR
What changed in CSBR news today?
Champions Oncology Q3 Services Revenue Rises 32% to $16.6M, EBITDA Positive: Champions Oncology reported Q3 services revenue record with core study revenue up 32% to $16.6M, delivering a third straight quarter of positive adjusted EBITDA at $575K. Total revenue slid 3% to $16.6M due to absence of data income and gross margin narrowed to 47% from 61%.
Does Rallies summarize CSBR news?
Yes. Rallies summarizes CSBR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CSBR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CSBR. It does not provide personalized investment advice.
